Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Implementing a letter template to expedite specialty medication appeal letter submission
Publication Year: 2025 Source: J Am Pharm Assoc (2003) PMID: 39374858 DOI: 10.1016/j.japh.2024.102262
BACKGROUND: Prior authorizations (PAs) for biologic medications, used to treat inflammatory bowel disease (IBD), are often denied by pharmacy benefits managers and can require a complex appeal process for patients to gain access to medication. OBJECTIVE: This quality improvement project evaluated the impact of implementing a standardized appeal letter template …
Calcitonin gene-related peptide promotes epithelial reparative and anticolitic functions of IL-4 educated human macrophages
Publication Year: 2025 Source: Am J Physiol Gastrointest Liver Physiol PMID: 39378308 DOI: 10.1152/ajpgi.00159.2024
Interleukin-4 activated human macrophages [M(IL4)s] promote epithelial wound healing and exert an anticolitic effect in a murine model. Blood monocyte-derived M(IL4)s from healthy donors and individuals with Crohn's disease had increased mRNA expression of the calcitonin gene-related peptide (CGRP) receptor chain, receptor activity modifying protein-1 (RAMP1), raising the issue of …
Early life exposures and risk of inflammatory bowel disease: A nested case-control study in Quebec, Canada
Publication Year: 2025 Source: Dig Liver Dis PMID: 39379227
No Abstract
Persistence of subcutaneous versus intravenous infliximab in a real-life cohort: A propensity-score matched comparative analysis
Publication Year: 2025 Source: Dig Liver Dis PMID: 39379232 DOI: 10.1016/j.dld.2024.09.015
BACKGROUND: There is limited comparative data on patients with inflammatory bowel disease (IBD) switched from intravenous to subcutaneous infliximab and those continuing intravenously. This study aimed to compare the persistence and tolerance of subcutaneous and intravenous infliximab and the outcomes of patients resuming intravenous infliximab. METHODS: We conducted a retrospective …
Beyond Depression and Anxiety in Inflammatory Bowel Diseases: Forging a Path Toward Emotional Healing
Publication Year: 2025 Source: Am J Gastroenterol PMID: 39382574 DOI: 10.14309/ajg.0000000000003125
Inflammatory bowel diseases (IBDs) are chronic, often debilitating diseases characterized by inflammation of the digestive tract. IBDs affect up to 1% of the world's population and tend to be diagnosed in the second and third decades of life. In addition to physical burdens, IBDs have significant psychological manifestations stemming from …
Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist
Publication Year: 2025 Source: Am J Gastroenterol PMID: 39382676 DOI: 10.14309/ajg.0000000000003119
Drug-induced acne is a common side effect to a wide array of pharmacological therapies and is characterized by a monomorphic, papulopustular eruption typically affecting the face, scalp, and the upper thorax. Corticosteroids and Janus kinase inhibitors (JAKi) are commonly used for the treatment of inflammatory bowel disease (IBD) and are …
Early Life Exposure to Parental Crohn's Disease Is Associated With Offspring's Gut Microbiome, Gut Permeability, and Increased Risk of Future Crohn's Disease
Publication Year: 2025 Source: Gastroenterology PMID: 39384162
No Abstract
The impact of colectomy and restorative procedure on pouch function after ileo-pouch-anal anastomosis in ulcerative colitis. The icon fun study on behalf of the Italian Society of Colon and Rectal Surgery (SICCR) Inflammatory Bowel Diseases committee
Publication Year: 2025 Source: Dig Liver Dis PMID: 39384458
No Abstract
Evaluating the Therapeutic Efficacy of Lactobacillus Strains in the Management of Ulcerative Colitis: An Overview of Recent Advances
Publication Year: 2025 Source: Curr Pharm Des PMID: 39385420 DOI: 10.2174/0113816128322653240925115114
Ulcerative Colitis (UC) known as a sub-category of Inflammatory Bowel Diseases (IBD) is a longterm condition that causes inflammation, irritation, and ulcers in the colon and rectum. Though the precise pathogenesis of UC is not fully understood yet, impaired immune responses and imbalanced intestinal microbiome composition have been regarded as …
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases
Publication Year: 2025 Source: Aliment Pharmacol Ther PMID: 39387155 DOI: 10.1111/apt.18318
BACKGROUND: Given the introduction of new advanced therapies for inflammatory bowel diseases (IBDs), expanded risk mitigation strategies are essential. AIMS: To create a comprehensive set of statements on assessment procedures and vaccinations before starting monoclonal antibodies, Janus kinase (JAK) inhibitors or sphingosine-1-phosphate (S1P) modulators for IBD. METHODS: We examined literature, …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide